Renin–angiotensin system inhibitors, beta‐blockers, and mineralocorticoid receptor antagonists have each been shown to reduce incident AF, and the low rate of new‐onset AF in the present trial may reflect the high usage of these drugs in DAPA‐HF.6, 15, 21, 22, 23. The gene discussed is NR3C2; the disease is atrial fibrillation.